drugset / Trial / NCT05714072
A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
Phase 1
Recruiting
18 enrolled
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company · collabIncyte Corporation · collab
NaSequentialOpen-labelOther
Summary
The study is being done to see if the combination of ruxolitinib and abemaciclib is a safe and effective treatment for people with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Timeline
- Start
- 2023-01-25
- Primary completion
- 2027-01
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 50 mg | — |
| Subject | Abemaciclib | Small molecule | 100 mg | — |
| Subject | Abemaciclib | Small molecule | 150 mg | — |
| Subject | Ruxolitinib | Small molecule | 10 mg | — |
| Subject | Ruxolitinib | Small molecule | 15 mg | — |